TB EEA's UK manager David Urch explains why he has been avoiding pricey defensives in favour of Shire Pharamaceuticals and Barratt Homes.
To continue reading this article...
Join Investment Week today
Free for those involved in advising, managing and/or analysing investments or £1 per day for professionals outside of these roles.
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
